Skip to content

A-LiNK: Improving Outcomes in Autoimmune Liver Disease

Autoimmune Liver Disease Network for Kids (A-LiNK): Using Patient Data to Transform Care and Improve Outcomes for Children, Adolescents, and Young Adults With Autoimmune Liver Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05750498
Acronym
ALINK
Enrollment
800
Registered
2023-03-01
Start date
2022-04-28
Completion date
2033-06-30
Last updated
2026-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Hepatitis, Primary Sclerosing Cholangitis

Keywords

Pediatrics, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, Autoimmune Sclerosing Cholangitis, Chronic Liver Disease, End-stage Liver Disease, Clinical Registry, Research Registry, Quality Improvement, Outcomes Research, Comparative Effectiveness Research, Patient Reported Outcomes, Health Services Research

Brief summary

The Autoimmune Liver disease Network for Kids (A-LiNK) is a multi-institutional group with the mission to deliver the best care to kids with pediatric autoimmune liver disease (AILD). This study will establish a shared clinical registry and a learning health network for the participating sites focusing on collecting and transmitting clinical measurement data, information about processes, and participation in an improvement collaborative. Pediatric Autoimmune Hepatitis (AIH) and Primary Sclerosing Cholangitis (PSC), represent a spectrum of AILD which present unique diagnostic and therapeutic challenges.A lack of accepted guidelines for disease monitoring or symptom management results in wide treatment variation with liver transplants indicated in refractory, progressive disease. The aims of A-LiNK are to: 1.) Create a learning health network focused on patient-centered outcomes research characterized by transparent sharing among centers, common priorities, and feasible plans for implementing new practices; 2) shift from traditional investigator-driven study to a patient and family-centered approach, and 3.) improve clinical outcomes and quality of life for pediatric AILD patients.

Interventions

OTHERNo interventions

There are no interventions

Sponsors

Children's Hospital Medical Center, Cincinnati
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of autoimmune hepatitis (AIH) * Clinical diagnosis of primary sclerosing cholangitis (PSC) * Clinical diagnosis of autoimmune sclerosing cholangitis (ASC)

Exclusion criteria

• History of liver transplant

Design outcomes

Primary

MeasureTime frameDescription
Baseline disease characteristics in the population2034
Disease relapse and biochemical remission rates2034Biochemical remission = transaminases (ALT/AST) within the upper limit of normal for age
Complications of disease2034Including ascites, esophageal variceal bleeding, cholangitis, hepatic encephalopathy, listed for liver transplant, hepatocellular carcinoma, or cholangiocarcinoma
Side-effects of steroids2034Including hypertension, diabetes mellitus, low bone mineral density, glaucoma, cataract, overweight, obesity
Pediatric Quality of Life Inventory (PedsQL 4.0) Generic Core Scales Short Form 152034Health-related quality of life
Racial and ethnic disparities2034

Countries

United States

Contacts

CONTACTAmy E Taylor, MD
amy.taylor@cchmc.org513-636-4415
CONTACTCyd M Castro-Rojas, PhD
cyd.castrorojas@cchmc.org5135170580
PRINCIPAL_INVESTIGATORAmy E Taylor, MD

Children's Hospital Medical Center, Cincinnati

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 20, 2026